Drug Shortage Listing or Supply Interruption Notice
A shortage listing is one of the few supply chain failures that gets published with its reason attached. The FDA and ASHP databases name the drug, the presentations affected, the companies still supplying, the stated cause, and the expected resolution. Each of those fields points at a different buyer: the manufacturer whose line went down and now has to fund quality and capacity remediation, the competitors absorbing demand they were not built for, and the health systems improvising substitution and sourcing. Avina detects new listings, status changes, and the quality events that precede them.
Why a Drug Shortage Is a Buying Signal for Sales Teams
A shortage listing is a public admission that a supply chain has failed, published with unusual specificity: the molecule, the presentations affected, the companies still supplying, the stated reason, and an expected resolution date. Most supply chain failures are invisible from outside. This one comes with a structured record. For the manufacturer whose interruption caused the listing, the cause is almost always quality or capacity — a sterile injectable line with an environmental monitoring problem, a single-source API supplier, an aging facility that failed an inspection. The response is funded quickly, because regulatory attention and reputational cost arrive together and neither waits for the annual budget cycle. That means capital equipment, single-use and fill-finish capacity, CDMO qualification, deviation and CAPA remediation, environmental monitoring and quality systems, and second-source API qualification, all on a compressed timeline. For competitors still on the market, a shortage is a demand spike they must serve without their own line going down. That funds capacity expansion, allocation management, and serialization-grade visibility into where inventory actually sits — plus, frequently, an accelerated regulatory filing to enter the shortage. For health systems and specialty pharmacies on the buying side, a shortage is an operational emergency: therapeutic substitution protocols, compounding capacity, allocation across sites, 503B outsourcing relationships, and inventory visibility across every dispensing location. Most health systems discover during a shortage that they cannot see their own on-hand stock across the network in real time. That discovery funds inventory and diversion-visibility platforms that had been deferred for years. Shortages also have a long tail — the median listing runs well past a year — so the buying window is wide rather than momentary, and the published resolution status tells you when it starts closing.
How Does Avina Detect Drug Shortages and Supply Interruptions?
Avina, an AI-powered GTM platform, monitors the FDA Drug Shortages Database and ASHP bulletins continuously and diffs them rather than re-reading them, so new listings, presentation-level changes, and resolution status updates are each treated as distinct events with their own timing. The stated reason is the field Avina extracts most carefully, because it determines who is buying what. A manufacturing quality cause points at remediation, equipment, and CDMO spending at a named company. Increased demand points at capacity and allocation problems across every remaining supplier. Discontinuation points at competitors filing to enter and at health systems replatforming a protocol. Avina also watches the events that precede a listing. Recalls, warning letters, import alerts, and inspection outcomes at a facility making a sole-source or narrow-market product are leading indicators, and an account surfaced at that stage is reached before the shortage is formalized and before every competing vendor is calling. On the demand side, Avina resolves listings to the health systems and pharmacies most exposed to them, and corroborates with hiring for pharmacy procurement, sourcing, and drug shortage coordinator roles — a role that exists only at organizations that have decided shortages are a permanent operating condition rather than an occasional disruption. Competitor entries and abbreviated application approvals aimed at a shortage are tracked as their own trigger, because a company scaling to fill a gap has a capacity problem on a deadline. Each account is enriched with its role in the shortage — interrupted supplier, remaining supplier, new entrant, or affected provider — along with facility footprint, dosage form and manufacturing profile, and existing quality and supply chain technographics, then matched against your ICP filters.
What Happens When a Drug Shortage Signal Fires?
Avina scores the account on its role in the shortage, the severity and breadth of the listing, whether the cause is one you address, and ICP fit. A sole-source manufacturer with a published quality cause scores highest for quality and capacity vendors. A large integrated delivery network exposed to a critical-care shortage scores highest for inventory, substitution, and outsourced compounding vendors. Timing is unusually forgiving here. New listings are urgent, but the long duration of most shortages means an account remains workable for quarters — and the published resolution status shows when the window is closing, which is information most sellers do not have. Contacts are enriched with verified emails, phone numbers, and LinkedIn profiles through waterfall enrichment. On the manufacturing side, Avina identifies the VP of quality, the head of manufacturing or technical operations, and the supply chain leader accountable for the interruption. On the provider side, it identifies the director of pharmacy, the pharmacy supply chain or procurement lead, and the drug shortage coordinator where one exists. Reps receive a Slack alert with the drug, the presentations affected, the stated reason, the account's role in the shortage, and the current resolution status. Salesforce and HubSpot records carry that context so the conversation starts from the specific interruption rather than from a general pitch about supply resilience. Qualified accounts can be auto-enrolled into Outreach or Salesloft sequences matched to your side of the market — quality systems, capacity and equipment, CDMO and second-source qualification, or inventory visibility, substitution management, and outsourced compounding. The opening that works names the listing. A head of quality dealing with a published shortage caused by their own facility already knows the problem; what they are evaluating is who can help fastest.
Start Tracking Drug Shortages With Avina
The FDA and ASHP publish every shortage with its cause, its affected presentations, and its resolution status. Activate this signal in Avina's Signals Library. Every plan includes a 7-day free trial with no credit card required.